2,6-Methano-3-benzazocine | 245-77-2

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 2,6-Methano-3-benzazocine
• 英文别名: 10-azatricyclo[7.3.1.02,7]trideca-1(12),2,4,6,8,10-hexaene
• CAS: 245-77-2
• 化学式: C₁₂H₉N
• 分子量: 167.21
• InChiKey: ZJFPQVBARDXZPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Peripherally Acting Opioid Compounds
  申请人：Blumberg Laura Cook

  公开号：US20130005755A1

  公开（公告）日：2013-01-03

  The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:

  这项发明涉及公式I、II、III、IV的化合物，或其药学上可接受的酯或前药。
• Process for the Synthesis of Substituted Morphinans
  申请人：Duncan Scott

  公开号：US20120010412A1

  公开（公告）日：2012-01-12

  The present invention relates to a process for the synthesis of a compound of formula I:

  本发明涉及一种用于合成化合物I的方法：
• [EN] QUATERNARY OPIOID CARBOXAMIDES<br/>[FR] CARBOXAMIDES OPIOÏDES QUATERNAIRES
  申请人：RENSSELAER POLYTECH INST

  公开号：WO2009023567A1

  公开（公告）日：2009-02-19

  Compounds of formulas (A) and (B) are disclosed. The compounds of this invention are useful for ameliorating the side effects of therapeutic opiates.

  本发明揭示了化合物(A)和(B)的配方。本发明的化合物对于缓解治疗阿片类药物的副作用很有用。
• 8-carboxamido-2,6-methano-3-benzazocines
  申请人：——

  公开号：US20030187009A1

  公开（公告）日：2003-10-02

  8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH 2 —OH, —CH 2 NH 2 , —NHSO 2 CH 3 , 1 and Y is O, S or NOH are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. 2 8-Carboxamides, thiocarboxamides, hydroxyamidines and formamides are preferred.

  通用结构I中的8-取代-2,6-甲烷基-3-苯并噁唑啉化合物，其中A为—CH2—OH，—CH2NH2，—NHSO2CH3，1和Y为O，S或NOH，可用作镇痛药、止泻药、抗惊厥药、止咳药和抗成瘾药物。28-羧酰胺、硫代羧酰胺、羟基胺和甲酰胺是首选。
• [EN] METHOD FOR INHIBITING GROWTH OF CANCER CELLS<br/>[FR] PROCÉDÉ POUR INHIBER LA CROISSANCE DE CELLULES CANCÉREUSES
  申请人：PAIN THERAPEUTICS INC

  公开号：WO2015054027A1

  公开（公告）日：2015-04-16

  1 A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Aktl, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC- labeled naloxone binding amount when present at a 10 μΜ concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of Figs. 19-24.

  本发明揭示了一种抑制癌细胞生长的方法，其中将相对于非癌细胞含有增强量的一个或多个磷酸化mTOR、Aktl、ERK2和丝氨酸2152-磷酸化filamin A的癌细胞与与filamin A（FLNA）的SEQ ID NO: 1的五肽结合并且在10μΜ浓度下至少表现出FITC标记的纳洛酮结合量的60％的化合物或其药学上可接受的盐接触。优选结合到FLNA五肽的化合物还包含Figs. 19-24中的六个药效团中的至少四个。